158 related articles for article (PubMed ID: 2805845)
1. Single daily-dose ofloxacin monotherapy for Mycobacterium fortuitum sternotomy infection.
Yew WW; Kwan SY; Ma WK; Khin MA; Mok CK
Chest; 1989 Nov; 96(5):1150-2. PubMed ID: 2805845
[TBL] [Abstract][Full Text] [Related]
2. Combination of ofloxacin and amikacin in the treatment of sternotomy wound infection.
Yew WW; Kwan SY; Ma WK; Aung-khin M; Mok CK
Chest; 1989 May; 95(5):1051-5. PubMed ID: 2707062
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial activity of ofloxacin and other agents against mycobacterial isolates from postoperative sternotomy wounds.
Yew WW; Kwan SY; Ma WK; Lui KS; Aung MK
Clin Ther; 1989; 11(6):775-85. PubMed ID: 2611821
[TBL] [Abstract][Full Text] [Related]
4. Postantibiotic effects of amikacin and ofloxacin on Mycobacterium fortuitum.
Tsui SY; Yew WW; Li MS; Chan CY; Cheng AF
Antimicrob Agents Chemother; 1993 May; 37(5):1001-3. PubMed ID: 8517688
[TBL] [Abstract][Full Text] [Related]
5. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities.
Wallace RJ; Swenson JM; Silcox VA; Bullen MG
J Infect Dis; 1985 Sep; 152(3):500-14. PubMed ID: 3875667
[TBL] [Abstract][Full Text] [Related]
6. Ofloxacin therapy of Mycobacterium fortuitum infection: further experience.
Yew WW; Kwan SY; Ma WK; Lui KS; Suen HC
J Antimicrob Chemother; 1990 May; 25(5):880-1. PubMed ID: 2373673
[No Abstract] [Full Text] [Related]
7. Clinical usefulness of amikacin and doxycycline in the treatment of infection due to Mycobacterium fortuitum and Mycobacterium chelonei.
Dalovisio JR; Pankey GA; Wallace RJ; Jones DB
Rev Infect Dis; 1981; 3(5):1068-74. PubMed ID: 7339806
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro and in vivo activity of fleroxacin and ofloxacin against various mycobacteria.
Tomioka H; Sato K; Saito H
Tubercle; 1991 Sep; 72(3):176-80. PubMed ID: 1771676
[TBL] [Abstract][Full Text] [Related]
9. Urinary Mycobacterium fortuitum infection.
Oren B; Raz R; Hass H
Infection; 1990; 18(2):105-6. PubMed ID: 2332244
[TBL] [Abstract][Full Text] [Related]
10. Sulfonamide activity against Mycobacterium fortuitum and Mycobacterium chelonei.
Wallace RJ; Jones DB; Wiss K
Rev Infect Dis; 1981; 3(5):898-904. PubMed ID: 7339821
[TBL] [Abstract][Full Text] [Related]
11. Levofloxacin alone efficiently treated a cutaneous mycobacterium fortuitum infection.
Fujita N; Utani A; Matsumoto F; Matsushima H; Kakuta M; Hatamochi A; Shinkai H
J Dermatol; 2002 Jul; 29(7):452-4. PubMed ID: 12184647
[TBL] [Abstract][Full Text] [Related]
12. Mycobacterium fortuitum infections of the mediastinum.
Sethi GK; Simons WJ; Scott SM
J Cardiovasc Surg (Torino); 1985; 26(3):307-9. PubMed ID: 3997975
[TBL] [Abstract][Full Text] [Related]
13. Minimal bactericidal and inhibitory concentrations of ofloxacin on Mycobacterium fortuitum at pH 7 and 5: therapeutic implications.
Yew WW; Kwan SY; Ma WK; Lui KS
Tubercle; 1990 Sep; 71(3):205-8. PubMed ID: 2238127
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Mycobacterium fortuitum isolates from sternotomy wounds by antimicrobial susceptibilities, plasmid profiles, and ribosomal ribonucleic acid gene restriction patterns.
Yew WW; Wong PC; Woo HS; Yip CW; Chan CY; Cheng FB
Diagn Microbiol Infect Dis; 1993; 17(2):111-7. PubMed ID: 7694821
[TBL] [Abstract][Full Text] [Related]
15. [Ofloxacin in the treatment of pulmonary changes caused by Mycobacterium avium and Mycobacterium xenopii].
Zwoliński J; Gałazka J
Pneumonol Alergol Pol; 1992; 60(5-6):70-3. PubMed ID: 1290992
[TBL] [Abstract][Full Text] [Related]
16. Infection due to organisms of the Mycobacterium fortuitum complex after augmentation mammaplasty: clinical and epidemiologic features.
Clegg HW; Foster MT; Sanders WE; Baine WB
J Infect Dis; 1983 Mar; 147(3):427-33. PubMed ID: 6833792
[TBL] [Abstract][Full Text] [Related]
17. Determination of the in vitro susceptibility of 220 Mycobacterium fortuitum isolates to ten antimicrobial agents.
Hernández AM; Arias A; Felipe A; Alvarez R; Sierra A
J Chemother; 1995 Dec; 7(6):503-8. PubMed ID: 8667033
[TBL] [Abstract][Full Text] [Related]
18. Mutational resistance as the mechanism of acquired drug resistance to aminoglycosides and antibacterial agents in Mycobacterium fortuitum and Mycobacterium chelonei. Evidence is based on plasmid analysis, mutational frequencies, and aminoglycoside-modifying enzyme assays.
Wallace RJ; Hull SI; Bobey DG; Price KE; Swenson JM; Steele LC; Christensen L
Am Rev Respir Dis; 1985 Aug; 132(2):409-16. PubMed ID: 4026065
[TBL] [Abstract][Full Text] [Related]
19. Port-site infections by nontuberculous mycobacterium: A retrospective clinico-microbiological study.
Ghosh R; Das S; De A; Kela H; Saha ML; Maiti PK
Int J Mycobacteriol; 2017; 6(1):34-37. PubMed ID: 28317802
[TBL] [Abstract][Full Text] [Related]
20. Clinical disease, drug susceptibility, and biochemical patterns of the unnamed third biovariant complex of Mycobacterium fortuitum.
Wallace RJ; Brown BA; Silcox VA; Tsukamura M; Nash DR; Steele LC; Steingrube VA; Smith J; Sumter G; Zhang YS
J Infect Dis; 1991 Mar; 163(3):598-603. PubMed ID: 1995732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
